For patients who are uninsured or underinsured, new treatments on the cutting edge of medicine called biosimilars have the potential to expand access and save lives.
On June 8, the state Senate debated House No. 2477/Senate No. 1705, which provides a pathway in New Jersey for access to lower-cost mimic therapies of expensive biologic drugs.
The bond between patients and healthcare providers has always been based on trust and transparency
The FDA’s approval of Zarxio, the first biosimilar product authorized for use in the United States, led to a flurry of predictions Friday about billions of dollars in savings and expanded access to treatment for patients. But what exactly are biosimilars, and why are they being hailed in this way?
Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products.